Skip to content
DataLookout
Menu

NCT07628881

A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Sep 27, 2026 to Sep 26, 2026
    • Secondary endpoints: details revised at 3 of 7 entries
    • Site details revised
  2. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 18, 2026 to Jun 17, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) for Sonrotoclax
Timeframe: Approximately 20 days
Area under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) for Sonrotoclax
Timeframe: Approximately 20 days
Maximum Observed Plasma Concentration (Cmax) of Sonrotoclax
Timeframe: Approximately 20 days

Secondary (7)

Time of the Maximum Observed Concentration (Tmax) for Sonrotoclax
Apparent Terminal Elimination Half-life (t1/2) for Sonrotoclax
Apparent Total Clearance (CL/F) for Sonrotoclax
Apparent Volume of Distribution (Vz/F) for Sonrotoclax
Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Show 2 moreShow less
Number of Participants with Abnormal Clinically Significant Electrocardiogram (ECG) Values
Number of Participants with Clinically Significant Vital Signs Measurements

Arms and interventions

Sonrotoclax Tablet for Oral SuspensionExperimental

Participants will receive each of the following treatments as a single dose on 3 separate occasions with an 8-day washout in between: 1. oral dose of sonrotoclax tablet for oral suspension administered in the fed state with a high-fat meal. 2. oral dose of sonrotoclax tablet for oral suspension administered after fasting 3. oral dose of sonrotoclax tablet administered in the fed state with a high-fat meal.

Drugs: Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet

Sites

1 site in 1 country

  • Linear Early PhaseJoondalup, Western Australia, Australia